OAK BROOK, Ill.--(BUSINESS WIRE)--Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged in the commercial development of vaccines for the prevention and treatment of human infectious diseases announced today that it had increased the size of its private placement by closing a sale of additional investment units. Each investment unit consists of a share of common stock, two series of common stock purchase warrants to purchase 0.5 share of common stock respectively. The offering of $1,450,000 of investment units was purchased by a director, Mr. Cheung Hin Shun Anthony.
